
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
Lymphoblastic LeukemiaAcute6 moreThis study is for patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Hodgkin's Disease (HD) or Non-Hodgkin's Lymphoma (NHL). Panobinostat is a new drug that is considered investigational because it has not been approved in the United States by the Food and Drug Administration (FDA), or in any other country. Panobinostat is a histone deacetylase inhibitor (HDACi) and interferes with gene expression found in cells causing them to stop growing or die. Panobinostat has been used in several hundred adults who had leukemia, HD, NHL and other solid tumors. Panobinostat has not been given to children. This is a phase I study. In a phase I study, drugs are tested to the highest dose that can be safely given. Drugs are given at gradually increasing dosages until there are unacceptable side effects. The goal of the Phase I study is to find out the dose of panobinostat that can be safely given to children with relapsed ALL, AML, HD and NHL.

A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory...
Chronic Myelogenous LeukemiaAcute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.

A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute...
Acute Lymphoblastic LeukemiaAcute Myelogenous Leukemia1 moreClofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. This use is based on the induction of complete responses. Randomized trials demonstrating increased survival or other clinical benefit have not been conducted. The purpose of the phase 1 portion of this study was to determine if clofarabine added to a combination of etoposide and cyclophosphamide is safe in children with relapsed or refractory acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). The purpose of the phase 2 portion of the study was to measure the effectiveness of the combination therapy in children with ALL.

Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive...
Accelerated Phase Chronic Myelogenous LeukemiaBlastic Phase Chronic Myelogenous Leukemia8 moreThis phase I trial is studying the side effects and best dose of dasatinib in treating young patients with recurrent or refractory solid tumors or Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myelogenous leukemia that did not respond to imatinib mesylate. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant...
LeukemiaMyeloid5 moreThe purpose of this clinical research study is to provide dasatinib treatment to patients with advanced chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who no longer can tolerate treatment with imatinib. The safety of the treatment will also be studied.

Vorinostat in Treating Patients With Acute Myeloid Leukemia
Adult Acute Erythroid Leukemia (M6)Adult Acute Megakaryoblastic Leukemia (M7)16 moreVorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for their growth. Giving the drug in different ways may kill more cancer cells. This randomized phase II trial is studying two different schedules of vorinostat to see how well they work in treating patients with acute myeloid leukemia.

AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous Leukemia
Refractory or Recurrent Solid TumorsAcute Myelogenous LeukemiaBackground: AZD2171 is an experimental drug that may slow the growth of cancers by blocking angiogenesis (formation of new blood vessels). Cancer growth is dependent on angiogenesis for nutrition. Inhibiting angiogenesis is a new approach to cancer therapy. Objectives: To determine the side effects of AZD2171 in children and adolescents with cancer. To determine the highest dose of AZD2171 that can safely be given to children and adolescents with cancer. To study how the body handles AZD2171. To determine the effects of AZD2171 on various factors related to angiogenesis. To determine if AZD2171 can inhibit cancer growth in children and adolescents. Eligibility: -Children and adolescents 2-18 years of age with treatment-resistant solid tumor cancers or acute myelogenous leukemia. Design: About 40 patients may be included in the study. AZD2171 is given by mouth in treatment cycles of once a day for 28 days. Treatment may continue unless the cancer worsens or unacceptable side effects develop. Patients have periodic physical examinations, blood and urine tests and imaging tests (CT, X-rays, MRI) to evaluate disease throughout the course of treatment. Additional blood tests are done to study how the body handles AZD2171, to look for proteins that stimulate angiogenesis, to determine if certain blood vessel cells are affected by AZD2171, and for other research purposes. Biopsy tissue (when available) is examined for the receptor for new blood vessel formation.

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed...
Chronic Myelogenous LeukemiaThe purpose of this study is to evaluate and compare the side effects and anti-leukemic benefits of imatinib with those of interferon and Ara-C for patients who have chronic myeloid leukemia (CML) in the chronic phase. Patients in this study will be randomized (1:1) to receive either interferon plus Ara-C or imatinib as initial treatment.

Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia...
Acute Myeloid LeukemiaThis study compares overall survival between patients with acute myeloid leukemia, who are in complete remission following initial treatment with chemotherapy and whose remission is maintained either with a transplantation of stem cells obtained from a sibling or unrelated donor or with standard treatment, which is additional chemotherapy. The study hypothesis is that the group transplanted with stem cells from a donor will have a superior survival compared with patients treated with standard of care.

MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed...
Acute Myelogenous LeukemiaThis is a phase 1, open-label, multicenter study investigating the use of MLN518 in combination with standard chemotherapy to patients with newly diagnosed AML. Two dose levels of MLN518-200 mg and 400 mg given orally twice a day are planned for sequential evaluation in separate groups of patients. Patients assigned to the 400 mg dose level given orally twice a day of MLN518, will potentially have their dose of MLN518 adjusted on the basis of MLN518 plasma concentrations measured during the first 3 days of induction therapy. All patients will receive initial induction chemotherapy with cytarabine, 200 mg/m2/day by CIVI on Days 1 through 7, and with daunorubicin, 60 mg/m2/day by intravenous (IV) push (IV infusion if borderline cardiac function is detected) on Days 1 through 3 ("7+3"). An abbreviated cytarabine and daunorubicin regimen ("5+2") will also be used when the initial remission induction therapy fails to clear the bone marrow of blast cells (as typically detected on the Day 15 bone marrow) and a second attempt at remission induction is indicated. Patients who achieve a complete remission (CR) will receive consolidation therapy with HiDAC (standard or modified) in combination with continued MLN518 treatment. Patients remaining in continuous CR after completion of their last cycle of consolidation therapy will be permitted to continue treatment with single-agent MLN518 for 6 months thereafter.